Delineate: Agents for Accelerated Clinical Trial Design | Y Combinator
Agents for Accelerated Clinical Trial Design
Delineate is building AI agents to design better clinical trials faster.
This is a $10B dollar market, where saving even 1 day along the process is equal to $1-5M in revenue potential.
We process existing clinical trial research into specialized datasets saving scientists months of effort.
Delineate is working with two of the largest pharmaceutical companies. With one of our customers, we are helping them get to the next phase of trials faster by creating the largest dataset on a drug class ever constructed.
Active Founders
Emily Nieves
Founder/CEO
Co-founder at Delineate. Previously she was an MIT PhD Candidate in Biological Engineering and worked at Pfizer and AstraZeneca where she focused on applying AI to modeling and simulation for drug development optimization.
Jawad Iqbal
Founder/CTO
Co-Founder and CTO of Delineate. Masters thesis in Robotics/AI with 2 research publications. Former technical project manager for high impact digital transformation projects within Skunkworks (Advanced Development) division at Lockheed Martin.
Company Launches
Delineate - Information Overload to Insights in Biopharma
TLDR
- Delineate extracts and analyzes data from biopharma research papers and patents at scale, including data trapped in figures and plots.
- We are partnered with two top-10 pharma companies where we are performing some of the largest systematic-review studies ever conducted.
- For our clients we have increased the number of processed studies by 15x compared to industry standard and reduced the time for certain studies from months to weeks.
Problem
90% of drug candidates fail despite billions in pharmaceutical R&D. Making evidence based decisions is crucial to the success of $2B drug pipelines. However to aggregate evidence across hundreds of research papers and patents can take research scientists months of hard labor.
Solution
Delineate has developed custom LLM and computer vision models paired with rigorous QC processes to deliver extremely high quality datasets in a fraction of the time. By increasing the scale and speed for evidence aggregation, Delineate is transforming how pharmaceutical companies make evidence based development decisions.
Demo:
Here is a quick demo of our platform and a sample project:
Ask:
- Any introductions to biopharma companies that perform meta-analyses and/or computational analysis workflows.
- If any biopharma-focused YC companies need assistance, we're happy to help!
About Us:
led by Emily Nieves (MIT PhD, former Pfizer/AstraZeneca computational researcher) and Jawad Iqbal (ex-Lockheed Skunkworks AI lead)
Delineate
Founded: 2024
Batch: Winter 2025
Team Size: 20
Status: Active
Location: Boston
Primary Partner: Jared Friedman
Company website
LinkedIn profile